...
首页> 外文期刊>Applied biochemistry and microbiology >Preparation of monoPEGylated human interferon beta-1a: Optimization of the conditions for N-terminal PEGylation
【24h】

Preparation of monoPEGylated human interferon beta-1a: Optimization of the conditions for N-terminal PEGylation

机译:单聚乙二醇化人干扰素β-1a的制备:N末端聚乙二醇化条件的优化

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The recombinant human interferon (IFN) beta-1a was modified with polyethylene glycol (PEG). The reaction was performed with the use of activated linear butyraldehyde PEG derivative with a molecular weight of 30 kDa. As a result of the multifactorial experiment, the correlation between the reaction conditions and the yield of the monoPEGylated protein was demonstrated and the optimal PEGylation conditions were established. We developed a one-step chromatographic purification scheme that makes it possible to obtain monoPEG-IFN beta-1a conjugate a purity above 98%. Mass-spectrometric studies showed that the purified conjugate is the PEGylated IFN beta-1a, in which the N-terminal methionine is bound with a PEG molecule. The molecular weight of the conjugate is 54130 Da. The obtained PEG-IFN beta-1a has a specific antiviral activity; it can be considered as a promising candidate in the design of prolonged-release medicine for the treatment of multiple sclerosis.
机译:重组人干扰素(IFN)β-1a用聚乙二醇(PEG)修饰。使用分子量为30kDa的活化的线性丁醛PEG衍生物进行反应。作为多因素实验的结果,证明了反应条件与单PEG化蛋白的产率之间的相关性,并确定了最佳PEG化条件。我们开发了一种一步色谱纯化方案,使获得纯度高于98%的monoPEG-IFNβ-1a共轭物成为可能。质谱研究表明,纯化的结合物是PEG化的IFNβ-1a,其中N端甲硫氨酸与PEG分子结合。结合物的分子量为54130Da。所获得的PEG-IFNβ-1a具有特定的抗病毒活性。在设计用于治疗多发性硬化症的延长释放药物中,它可以被认为是有前途的候选药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号